Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeMD, Inc. filings document the formal disclosures for the virtual primary care company and its listed securities, including common stock and the 8.875% Series A Cumulative Perpetual Preferred Stock. Form 8-K reports cover operating results, financial condition, earnings guidance, Regulation FD investor presentations, and executive officer changes.
Definitive proxy materials describe annual meeting procedures, board and governance matters, compensation-related disclosures, and stockholder voting items. The filing record also identifies the preferred security within the company's capital structure, including matters relevant to LFMDP holders such as preferred-stock status and related public-company disclosures.
Federated Hermes, Inc. reports shared beneficial ownership of 2,747,655 shares of LifeMD common stock, representing 5.68% of the class as of 06/30/2026. The filing lists voting and dispositive power as shared among Federated Hermes, the Voting Shares Irrevocable Trust, and named individuals and includes Rule 13d-4 disclaimers about beneficial ownership.
LifeMD, Inc. entered into an exclusive strategic co-marketing collaboration with Antares Pharma, a Halozyme subsidiary, to support a direct-to-patient self-pay program for XYOSTED, a once-weekly subcutaneous testosterone auto-injector. The program is expected to launch in July 2026 and will initially be available in 37 states.
LifeMD will act as the exclusive telehealth co-marketing partner, providing virtual clinician evaluation through its affiliated medical group and using its pharmacy as the preferred dispensing pharmacy to ship XYOSTED directly to patients’ homes. Both companies will jointly invest in consumer education and promotional initiatives about testosterone deficiency and the program.
The agreements have an initial three-year term with automatic one-year renewals, include a joint steering committee for governance, and allow either party to terminate the Statement of Work if budgeted co-marketing investments are not met for two consecutive quarters.
LifeMD, Inc. reported that Chief Technology Officer Sripad Umesh received an award of 75,000 shares of Common Stock as a grant or other acquisition. The award carries a zero dollar price per share, indicating it is compensation rather than an open-market purchase.
According to the footnote, this grant consists of restricted stock units that vest over time: 25,000 units on June 1, 2027, another 25,000 units on June 1, 2028, and the remaining units on June 1, 2029. Following this award, Umesh holds 75,000 shares directly, reflecting a new equity position that vests in stages over three years.
LifeMD, Inc. filed an initial ownership report on Form 3 for Sripad Umesh, who serves as Chief Technology Officer. The filing identifies him as an officer and not a ten percent owner. It reports no share transactions or derivative holdings at this time.
Kavthekar Atul reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that its Chief Financial Officer, Atul Kavthekar, received a grant of 337,500 shares of Common Stock in the form of restricted stock units. The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than a market purchase.
Following this grant, Kavthekar directly holds 337,500 shares. The units vest over time: 112,500 shares on March 16, 2027, another 112,500 shares on March 16, 2028, and the remaining portion on March 16, 2029, aligning his compensation with multi‑year service.
LifeMD, Inc. has issued its 2026 proxy statement for a virtual annual meeting on June 12, 2026, asking stockholders to elect seven directors, ratify PricewaterhouseCoopers as auditor, approve changes to its equity plan, and authorize possible adjournment of the meeting.
The Fourth Amended and Restated 2020 Equity and Incentive Plan would add 3,000,000 shares, remove the evergreen annual share increase, tighten share-counting rules, and prohibit option repricing without stockholder approval. The filing also describes a “little r” restatement-driven clawback of 392,000 shares of performance stock, valued at $1,336,720, and notes that 2025 formula bonuses under the corporate plan paid out at 0%, with the CEO’s 2025 total compensation at $777,075.
Pisano Christopher A reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that Chief Marketing Officer Christopher A. Pisano received a grant of 200,000 shares of common stock in the form of restricted stock units on March 30, 2026. The award carries no purchase price.
According to the vesting terms, 50,000 units vest on the grant date, and an additional 50,000 units also vest on the grant dateMarch 30, 2027. A further 50,000 units vest on March 30, 2027, with the remaining units vesting on March 30, 2028, aligning the compensation with continued service at the company.
LifeMD, Inc. executive Christopher A. Pisano, the company’s Chief Marketing Officer, filed an initial Form 3 as a reporting person. The filing lists no transactions or holdings, serving as a baseline disclosure of his status as an officer subject to insider reporting rules.